InvestSMART

Invion Limited (ASX:IVX)

ALERT: Price-sensitive ASX Announcement for IVX
Current share price for IVX : $0.041 -0.021 (-33.87%)+
Announcement
Release
30 Apr 2026 11:40AM
Price at Release
$0.062
Full Release
download
Summary
Invion Limited reported key advancements in its Photosoft™ platform for cancer treatment in its quarterly activities report ending March 31, 2026. The company received funding for preclinical studies on oesophageal cancer and is expanding its non-melanoma skin cancer trial to include patients with Basal Cell Carcinoma. Invion secured commitments of $1.3 million through a convertible note offering to support ongoing clinical trials and partner-funded studies. The company ended the quarter with $395K in cash reserves and anticipates receiving further funds upon shareholder approval. Invion continues to focus on developing its Photosoft™ technology as a novel photodynamic therapy for cancer and infectious diseases.
Key Points
  • Received ~$200K funding for oesophageal cancer preclinical studies.
  • Expanded non-melanoma skin cancer trial to include Basal Cell Carcinoma patients.
  • Secured $1.3 million in a convertible note offering.
  • Held $395K in cash reserves at the end of the quarter.
  • Photosoft™ technology is being developed for cancer and infectious diseases treatment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.